The CSL Limited (ASX:CSL) share price is down 24% from its peak – is it time to buy?

The CSL Limited (ASX: CSL) share price is down 24% from its 52 week high. Are the shares cheap now?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is down 24% from its 52-week high of $232 per share and whilst the broader market has also suffered in recent weeks, it's worth considering whether now is a good time to buy CSL shares.

The quality of CSL as a business is well known. It is one of the ASX's premier biotechnology companies along with Mayne Pharma Group Ltd (ASX: MYX) and Clinuvel Pharmaceuticals Limited (ASX: CUV). It has also managed to grow revenues and profits consistently while continuing to serve a large market.

The challenge for investors who don't already own CSL shares is that the market recognises that quality and reflects it in the share price. As such, the valuation of the company's shares has always been quite high.

So, with the shares down 24% from their peak, is now a good time to buy CSL shares? Let's look at a few metrics.

FY 2018 FY 2017
Revenue US$7,915 million US$6,947 million
Net Profit US$1,729 million US$1,337 million
Profit Margin 22% 19%
Market Cap A$80 billion (approx US$57 billion) Approx A$74 billion (US$52 billion) as at 30 June 2017
Price to Sales ratio 7.2 times 7.5 times
Price to Earnings ratio 33 times 39 times
Sales Growth rate (1 yr forecast) 9%
Underlying Profit Growth rate (1 yr forecast) 10% – 14%

*Source: CSL annual report and investor presentation

Interestingly, CSL's profit margins are expanding which is why the company is expecting profit growth to be higher than sales growth.

CSL's FY 18 dividend was US$1.51 per share, its current share price is A$177 (approx US$126) and I estimate a 12% expected annual return on CSL shares (equities as an asset class tend to average about 10% over time and I would expect CSL to perform better than average).

Given that information, I estimate that CSL is trading at an implied growth rate of 10% – 12%.

As such, I think CSL shares are fairly priced at the moment. I don't think they are ridiculously cheap, and I also don't think they are too expensive.

What now?

Since there is no margin for error in my back of the envelope calculations, I'm not jumping in to buy CSL shares right now. If the shares dip a little further, then I will definitely be tempted to open a position although I'm fully aware that this might not happen.

Instead, I might focus on these three revolutionary companies.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. You can find Kevin on Twitter @KevinGandiya. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »